# A Trial of Tocilizumab in ALS Subjects

> **NCT02469896** · PHASE2 · COMPLETED · sponsor: **Barrow Neurological Institute** · enrollment: 22 (actual)

## Conditions studied

- ALS
- Amyotrophic Lateral Sclerosis
- Lou Gehrig's Disease
- Motor Neuron Disease

## Interventions

- **DRUG:** Tocilizumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02469896
- **Lead sponsor:** Barrow Neurological Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2018-07-11
- **Final completion:** 2018-07-11
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2019-12-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02469896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02469896, "A Trial of Tocilizumab in ALS Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02469896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*